Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking
This article was originally published in The Pink Sheet Daily
Executive Summary
The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.
You may also be interested in...
FDA Review Should Be More Like Business Negotiation, Orexigen CEO Says
Having seen the “worst of ambiguity and then the greatest of clarity” from FDA, Mike Narachi concludes that “what’s lacking in the U.S. review process is leadership and decision-making that’s transparent to the sponsor.”
If At First You Don’t Succeed, Try Dispute Resolution
More companies are turning to CDER’s formal appeals process when presented with a review division’s regulatory decision or advice. Even though few appeals are granted in full, many sponsors get valuable clarity on a path forward; some appeals, like that for Amarin’s Vascepa SPA, are turned away at the door.
Obesity Drugs Covered By One-Third Of Large Employers In Survey
The National Business Group on Health survey illustrates the continuing reimbursement challenges faced by the recently introduced obesity drugs Qsymia and Belviq.